260 related articles for article (PubMed ID: 27515027)
1. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
Wu J; Jordan M; Waxman DJ
BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
[TBL] [Abstract][Full Text] [Related]
2. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
Wu J; Waxman DJ
Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts.
Doloff JC; Waxman DJ
BMC Cancer; 2015 May; 15():375. PubMed ID: 25952672
[TBL] [Abstract][Full Text] [Related]
4. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8
Wu J; Waxman DJ
Oncoimmunology; 2015 Apr; 4(4):e1005521. PubMed ID: 26137402
[TBL] [Abstract][Full Text] [Related]
5. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
Jordan M; Waxman DJ
Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
[TBL] [Abstract][Full Text] [Related]
6. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models.
Du B; Waxman DJ
Cancer Lett; 2020 Feb; 470():170-180. PubMed ID: 31765733
[TBL] [Abstract][Full Text] [Related]
7. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
[TBL] [Abstract][Full Text] [Related]
8. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.
Chen CS; Doloff JC; Waxman DJ
Neoplasia; 2014 Jan; 16(1):84-96. PubMed ID: 24563621
[TBL] [Abstract][Full Text] [Related]
9. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.
Doloff JC; Waxman DJ
Cancer Res; 2012 Mar; 72(5):1103-15. PubMed ID: 22237627
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2.
Doloff JC; Chen CS; Waxman DJ
Mol Cancer; 2014 Jun; 13():158. PubMed ID: 24965046
[TBL] [Abstract][Full Text] [Related]
11. Delicate Balances in Cancer Chemotherapy: Modeling Immune Recruitment and Emergence of Systemic Drug Resistance.
Tran AP; Ali Al-Radhawi M; Kareva I; Wu J; Waxman DJ; Sontag ED
Front Immunol; 2020; 11():1376. PubMed ID: 32695118
[TBL] [Abstract][Full Text] [Related]
12. Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine breast cancer.
Vergato C; Doshi KA; Roblyer D; Waxman DJ
Cancer Res Commun; 2022 Apr; 2(4):246-257. PubMed ID: 36187936
[TBL] [Abstract][Full Text] [Related]
13. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
14. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2001 Jun; 61(11):4437-44. PubMed ID: 11389073
[TBL] [Abstract][Full Text] [Related]
15. Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.
Jia L; Waxman DJ
Cancer Lett; 2013 Apr; 330(2):241-9. PubMed ID: 23228633
[TBL] [Abstract][Full Text] [Related]
16. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.
Alizadeh D; Zhang L; Brown CE; Farrukh O; Jensen MC; Badie B
Clin Cancer Res; 2010 Jul; 16(13):3399-408. PubMed ID: 20570924
[TBL] [Abstract][Full Text] [Related]
17. Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine.
Doloff JC; Khan N; Ma J; Demidenko E; Swartz HM; Jounaidi Y
Curr Cancer Drug Targets; 2009 Sep; 9(6):777-88. PubMed ID: 19754361
[TBL] [Abstract][Full Text] [Related]
18. Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway.
Zhong H; Lai Y; Zhang R; Daoud A; Feng Q; Zhou J; Shang J
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023984
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
20. Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice.
Bu N; Wu H; Zhang G; Zhan S; Zhang R; Sun H; Du Y; Yao L; Wang H
J Mol Neurosci; 2015 Jul; 56(3):631-43. PubMed ID: 25680514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
